The heat of AI investment and the feet of people

Today's article has two numbers lined up. Isomorphic Labs has raised $5 billion to advance AI-designed drugs into clinical trials. Imperial Brands will cut up to 4,600 jobs as it uses AI to save money. Where money comes in and where people lose money appear in the same technology articles on the same day. Former SEC Chairman Gensler and the Federal Reserve have expressed caution about overheating. What readers will change their judgment about in this half-day is not so much how far AI has advanced, but rather where the money is going and where the people and systems that didn't get into it are. The following sections will examine these two points in turn.
Isomorphic Labs has completed a $5 billion Series C raise to advance AI-designed drugs into clinical trials (Dealroom, BigGo Finance). The Hassabis-backed company's procurement was reported in British newspapers as the British tech entrepreneur raised $5 billion for an AI drug discovery company (The Telegraph). Funding for AI drug discovery has reached a scale that supports not only the research stage but also the costly process of clinical trials (AI Insider).
Funding is not just for raising startups. MedTex 2026 focused on US$12 billion in capital, treating the journey from AI drug discovery to acquisition of major pharmaceutical companies as a continuum (GeneOnline). As an example of an acquisition, Eli Lilly acquired Calytrix for $1.5 billion, acquiring rare blood disease assets. The same article also notes that the drop in Nvidia stock is weighing on AI-related deals (BigGo Finance). Expenditures have also increased significantly. Healthcare AI spending reached $3.7 billion, of which drug discovery increased 28.6 times (FourWeekMBA). Furthermore, the ``one-person pharmaceutical company'' that Anthropic acquired has been introduced as an example of how AI can support a small drug discovery startup (NewsPicks).
What the reader should check is what these numbers indicate. The $5 billion is for clinical trials, and the material has not shown any clinical results. The $1.5 billion acquisition of Lilly brings in rare blood disease assets, which is separate from the track record of AI-driven drugs. The fact that expenditures increased 28.6 times indicates that funds were directed toward drug discovery. It is necessary to separately confirm whether the drug was delivered as medicine or not. The point that AI-related transactions are affected by the decline in Nvidia stock also shows that valuations can go up and down depending on the market mood. Reading the size of funding as evidence of results may lead to erroneous decisions.
